PAVmed (PAVM) Stock Price, News & Analysis

Company Overview

PAVmed Inc. is a clinical-stage medical technology company focused on acquiring, developing and commercializing innovative medical devices aimed primarily at gastrointestinal endoscopy and related therapeutic areas. Its portfolio includes FDA-cleared products such as EsoFLIP® Distensibility System for the treatment of esophageal strictures and MUSE™ (Medigus Ultrasonic Surgical Endostapler) for endoscopic fundoplication in gastroesophageal reflux disease (GERD). In addition to its gastrointestinal franchise, PAVmed is advancing early-stage programs targeting indications in oncology, urology and dermatology.

Founded in 2012, PAVmed has built its pipeline through internal research and development as well as strategic collaborations and acquisitions. The company completed its initial public offering in 2017 and maintains research, development and regulatory operations in North America and strategic partnerships in Europe. PAVmed’s multidisciplinary team leverages clinical insights, engineering expertise and regulatory know-how to shepherd devices from concept through pivotal studies and commercialization.

PAVmed’s executive leadership brings together seasoned professionals from the medical device, clinical practice and regulatory sectors. The management team emphasizes streamlined regulatory pathways and robust clinical trial design, seeking to deliver less-invasive treatment options that address high unmet needs. Though based in the United States, the company’s regulatory clearances and distribution agreements extend into key international markets.

Looking ahead, PAVmed is focused on driving commercial adoption of its approved devices while advancing its mid- and late-stage programs toward pivotal data readouts and regulatory submissions. By targeting areas where minimally invasive approaches can improve patient outcomes and reduce healthcare costs, the company aims to establish sustainable growth through a diversified pipeline of differentiated medical technologies.

Key Stats

• Today's Range: $4.90 to $5.38
• 50-Day Range: $4.21 to $6.30
• 52-Week Range: $3.85 to $28.44
• Volume: 66,483 shs
• Average Volume: 48,348 shs
• Market Capitalization: $42.24 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $56.00
• Consensus Rating: Hold

PAVmed Stock Analysis - MarketRank™

PAVmed scored higher than 47% of companies evaluated by MarketBeat, and ranked 539th out of 911 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Hold

Consensus Rating

PAVmed has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 1 hold rating, and 1 sell rating.

Upside Potential

PAVmed has a consensus price target of $56.00, representing about 960.6% upside from its current price of $5.28.

Amount of Analyst Coverage

PAVmed has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for PAVmed are expected to grow in the coming year, from ($2.74) to ($2.55) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of PAVmed is -0.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of PAVmed is -0.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

PAVmed has a P/B Ratio of 2.74. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.33% of the float of PAVmed has been sold short.

Short Interest Ratio / Days to Cover

PAVmed has a short interest ratio ("days to cover") of 0.28, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in PAVmed has recently increased by 10.96%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

PAVmed does not currently pay a dividend.

Dividend Growth

PAVmed does not have a long track record of dividend growth.

News and Social Media

• Score: 2.3 / 5
• News Sentiment: N/A

News Sentiment

PAVmed has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.77 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 1 news article for PAVmed this week, compared to 2 articles on an average week.

MarketBeat Follows

3 people have added PAVmed to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, PAVmed insiders have not sold or bought any company stock.

Percentage Held by Insiders

13.40% of the stock of PAVmed is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

19.93% of the stock of PAVmed is held by institutions.

Company Calendar

• Last Earnings: 5/14/2026
• Today: 9/06/2026
• Next Earnings (Estimated): 11/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Equipment
• Current Symbol: NASDAQ:PAVM
• CIK: 1624326
• Web: www.pavmed.com
• Phone: (212) 949-4319
• Fax: N/A
• Employees: 90
• Year Founded: 2014

Price Target and Rating

• Average Price Target for PAVmed: $56.00
• High Price Target: $56.00
• Low Price Target: $56.00
• Potential Upside/Downside: +960.6%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($16.05)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $400 thousand
• Net Margins: -10,794.64%
• Pretax Margin: -14,669.64%
• Return on Equity: -126.43%
• Return on Assets: -25.49%

Debt

• Debt-to-Equity Ratio: 0.98
• Current Ratio: 1.19
• Quick Ratio: 1.19

Sales & Book Value

• Annual Sales: $70 thousand
• Price / Sales: 603.43
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.93 per share
• Price / Book: 2.74

Miscellaneous

• Outstanding Shares: 8,000,000
• Free Float: 6,925,000
• Market Cap: $42.24 million
• Optionable: No Data
• Beta: 0.53